Trial reportArthritis research & therapy2026
The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide.
Trial report in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundJuvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children and is characterized by chronic joint inflammation driven by immune dysregulation. A disturbed regulatory T (Treg) cell-effector T cell axis has been demonstrated in these patients which contributes to a dysregulated immune tolerance in JIA. Therefore, strategies to enhance Treg numbers and suppressive capacity to restore immune homeostasis represent a promising therapeutic approach. Nicotinamide (NAM), a form of vitamin B₃ and precursor of nicotinamide adenine dinucleotide (NAD⁺), has emerged as an immunomodulator capable of promoting Treg cell function.
methodsHere, we investigate the effects of NAM on Treg percentages and suppressive capacity in mononuclear cells derived from peripheral blood (PBMCs) and synovial fluid of JIA patients (SFMCs). In an exploratory pilot phase II clinical study, NAM concentrations were measured in paired blood plasma and SF from 6 JIA patients after oral administration of daily 1.8 g/m
resultsNAM treatment significantly increased the proportion of FOXP3-expressing CD4
conclusionGiven its established safety in both adults and children, NAM represents a promising future candidate for adjunctive therapy in JIA by restoring the balance between regulatory and effector T cells. Further clinical and mechanistic studies are warranted to define optimal dosing regimens and its place in the long-term treatment strategy of JIA.
trial registrationAssessing penetration of high dose nicotinamide (Vitamin B3) in synovial fluid. EudraCT Number: 2018-002245-11, start date Jan 16th, 2019.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.